NeRRe: Advancing Neurokinin Receptor Antagonists

Starting the year with a cash injection of £23m, 2012 GSK spin-out NeRRe Therapeutics intends to advance its neurokinin receptor antagonist pipeline towards late-stage clinical development. CEO Mary Kerr spoke to Scrip's Mike Ward at the 2017 Biotech Showcase in San Francisco.

Video interview
NeRRe Therapeutics' Mary Kerr speaks to Scrip

NeRRe Therapeutics Ltd., which was spun out of GlaxoSmithKline PLC in 2012, is advancing a pipeline of neurokinin receptor antagonists through the clinic, and earlier this year raised £23m. CEO Dr Mary Kerr explains how the company plans to generate Phase II data on orvepitant, a chronic respiratory candidate; and to advance NT-814 as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

NeRRe's products originated in GSK and were taken over when the UK big pharma decided to deprioritize neurosciences and spin...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.